Pharmaceutical

Walden Biosciences teams up with Primula for kidney disease study 

Walden reported positive topline data from a Phase I clinical trial of its lead candidate WAL0921, a humanised mAb to treat kidney disease.

May 15, 2024 - 04:00
Walden Biosciences teams up with Primula for kidney disease study 
Walden reported positive topline data from a Phase I clinical trial of its lead candidate WAL0921, a humanised mAb to treat kidney disease.
Read the original article

Tags:

Previous Article

Bayer reports drop in Q1 sales amidst patent litigation challenges

Next Article

AbbVie makes psychedelic play with $2bn Gilgamesh collaboration

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Israeli company bags $4.2m contract to develop cell therapy for radiation poisoning

Israeli company bags $4.2m contract to develop cell the...

Jul 11, 2023

Signal: Kroger to pay up to $1.4bn to settle opioid crisis lawsuits

Signal: Kroger to pay up to $1.4bn to settle opioid cri...

Sep 11, 2023

Providers still hesitate to prescribe buprenorphine for addiction, despite ‘X-waiver’ removal

Providers still hesitate to prescribe buprenorphine for...

Jul 22, 2023